Dr Reddys Laboratories will host an in-person group meeting with Nomura in Hyderabad on September 25, 2026. The session is scheduled to run from 11:00 am to 2:00 pm.

The company issued the intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This disclosure outlines the schedule for analyst and institutional investor meetings.

Meeting Details

The schedule remains subject to change due to exigencies on the part of investors or the company. K Randhir Singh, Company Secretary and Compliance Officer, signed the disclosure on September 21, 2026.

Dr. Reddy's Laboratories has entered into an exclusive distribution and marketing agreement with Takeda Biopharmaceuticals India Private Limited for Qdenga, a dengue vaccine developed by Takeda. The deal was announced on September 18, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Under the terms of the agreement, Dr. Reddy's will hold exclusive rights to distribute and market Qdenga in India's private sector for both pediatric and adult patients. Takeda will retain commercialization rights for the public market in India and remains responsible for the manufacturing and importation of the vaccine.

Market Context and Regulatory Approval

Qdenga received marketing authorization from India's Central Drugs Standard Control Organization (CDSCO) in July 2026 for individuals aged 4 to 60 years. It is the first dengue vaccine approved in India. The vaccine is anticipated to become available in the first half of 2027, subject to the completion of applicable processes with local authorities.

The collaboration addresses a significant public health challenge. Dengue cases in India have increased 11-fold over the past two decades. A nationwide surveillance study by the Indian Council of Medical Research indicates that all four dengue virus serotypes are co-circulating across multiple regions, with one in 14 patients infected with multiple serotypes concurrently.

Strategic Rationale

Dr. Reddy's stated that the partnership aligns with its strategy to strengthen its vaccines business in India. As the second-largest vaccine player in India, the company aims to contribute to efforts addressing the country's dengue burden. Takeda highlighted the growing recognition of dengue as a public health challenge, noting recent recommendations by the Parliamentary Committee on Health to consider the vaccine for the Universal Immunization Program.

While inclusion in the public immunization program remains a long-term ambition, the private-market availability through Dr. Reddy's provides an immediate pathway for eligible individuals to access the vaccine. Takeda retains legal ownership and overall medical and brand oversight rights for Qdenga in India.

What the Numbers Show

The agreement involves no upfront consideration or milestone payments from Dr. Reddy's to Takeda. This structure suggests a low-risk entry for Dr. Reddy's into the dengue vaccine segment, with financial returns dependent entirely on future sales volume rather than immediate capital outlay. The absence of upfront costs contrasts with typical biopharma licensing deals, potentially preserving cash flow while leveraging Dr. Reddy's existing commercial network.

Global Vaccine Profile

Qdenga is a live-attenuated tetravalent dengue vaccine built on a DENV-2 backbone with structural proteins from DENV-1, DENV-3, and DENV-4. It requires a two-dose regimen administered three months apart. The vaccine has been approved in 43 countries since 2022. More than 32 million doses have been distributed worldwide through public and private programs in Asia, Latin America, and Europe.

The World Health Organization has recommended Qdenga without pre-vaccination screening for use in high-endemic countries and listed it in its List of Prequalified Vaccines. The seven-year pivotal Phase 3 TIDES trial demonstrated overall efficacy across all four dengue virus serotypes.